



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

May 2022





© 2022 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

May 2022

N = 7479



Health Authority	Male	Female	All
FRASER	1469	450	1919
INTERIOR	429	114	543
NORTHERN	145	80	225
VANCOUVER COASTAL	3330	442	3772
VANCOUVER ISLAND	812	164	976
	6185	1250	7435
		Unknown/not stated:	44
		Total:	7479

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (May 2017 - May 2022)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (May 2017 - May 2022)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (May 2017 - May 2022)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (May 2017 - May 2022)






1.6 Percent Distribution of Active Participants by CD4 Count (May 2017 - May 2022)






1.7 Percent Distribution of Inactive Participants by CD4 Count (May 2017 - May 2022)






1.8 Active and Inactive Participants (May 2017 - May 2022)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (May 2017 - May 2022)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (May 2017 - May 2022)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(May 2017 - May 2022)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (May 2017 - May 2022)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(May 2017 - May 2022)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (May 2017 - May 2022)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(May 2017 - May 2022)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (May 2017 - May 2022)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(May 2017 - May 2022)






1.18 Baseline CD4 for Antiretroviral First Starts
(May 2017 - May 2022)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (May 2017 - May 2022)






1.20 Cumulative Resistance Testing Results by Resistance Category (May 2017 - May 2022)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (May 2017 - May 2022)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2022
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	30	4	0	4	1	950	4	<40	4
1988	31	5	0	5	3	400	5	<40	3
1989	29	51	1	52	26	490	47	<40	3
1990	28	53	1	54	31	580	53	<40	3
1991	28	37	3	40	19	620	39	<40	3
1992	28	54	5	59	22	540	52	<40	3
1993	27	120	14	134	82	505	126	<40	3
1994	25	73	12	85	57	540	79	<40	3
1995	25	123	20	143	86	525	133	<40	3
1996	23	313	47	360	221	550	332	<40	3
1997	21	263	33	296	178	615	269	<40	3
1998	21	183	40	223	135	520	197	<40	3
1999	21	153	39	192	119	560	170	<40	3
2000	21	115	28	143	88	615	127	<40	3
2001	20	112	27	139	87	550	129	<40	3
2002	19	117	26	143	98	540	129	<40	3
2003	19	136	25	161	108	625	151	<40	3
2004	18	149	36	185	123	610	172	<40	3
2005	17	180	41	221	152	620	208	<40	3
2006	16	172	39	211	137	590	189	<40	3
2007	15	226	45	271	178	620	244	<40	3
2008	14	274	63	337	227	666	305	<40	3
2009	13	299	66	365	239	622	329	<40	3
2010	12	263	67	330	213	680	293	<40	3
2011	11	320	67	387	254	700	356	<40	3
2012	10	265	63	328	206	730	299	<40	3
2013	9	247	66	313	209	670	278	<40	3
2014	8	264	49	313	192	700	278	<40	3
2015	7	262	41	303	203	714	270	<40	3
2016	6	250	53	303	188	675	256	<40	3
2017	5	213	31	244	170	655	226	<40	3
2018	4	190	56	246	165	740	216	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2022
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	3	228	39	267	192	675	241	<40	3
2020	2	188	54	242	179	720	212	<40	3
2021	1	210	40	250	172	575	227	<40	3
2022	0	89	18	107	92	620	104	<40	3
Total:		6201	1255	7456					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2021	7385	745	1942	<40	1393	630
FEB-2021	7378	748	1787	<40	1276	630
MAR-2021	7433	743	2015	<40	1429	620
APR-2021	7417	746	1828	<40	1324	636
MAY-2021	7452	742	1868	<40	1306	630
JUN-2021	7456	738	1880	<40	1355	610
JUL-2021	7460	744	1820	<40	1347	640
AUG-2021	7465	741	1981	<40	1354	630
SEP-2021	7432	750	1763	<40	1248	630
OCT-2021	7432	755	1855	<40	1291	630
NOV-2021	7446	750	2021	<40	1378	630
DEC-2021	7462	757	1543	<40	1039	630
JAN-2022	7465	756	1878	<40	1313	650
FEB-2022	7386	774	1803	<40	1249	620
MAR-2022	7458	766	1904	<40	1234	624
APR-2022	7422	776	1756	<40	1128	625
MAY-2022	7479	762	1999	<40	1266	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2021	773	196	73	<40	56	525
FEB-2021	785	196	69	<40	56	510
MAR-2021	769	247	89	<40	71	630
APR-2021	803	255	73	<40	58	615
MAY-2021	781	270	73	<40	65	530
JUN-2021	779	262	65	57	49	540
JUL-2021	780	274	52	102	37	530
AUG-2021	786	263	53	<40	43	630
SEP-2021	829	227	64	<40	41	610
OCT-2021	832	240	79	<40	60	540
NOV-2021	816	263	78	<40	61	450
DEC-2021	796	248	48	<40	32	385
JAN-2022	788	273	55	<40	42	613
FEB-2022	858	233	73	<40	55	620
MAR-2022	802	285	94	<40	72	499
APR-2022	836	281	69	<40	52	550
MAY-2022	778	340	59	<40	42	490

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2021	7359	773	14	9	205	159	37	14210
FEB-2021	7352	785	15	13	186	189	-7	14234
MAR-2021	7405	769	15	24	203	156	53	14271
APR-2021	7390	803	13	9	165	173	-15	14296
MAY-2021	7418	781	14	14	177	143	28	14325
JUN-2021	7435	779	7	15	186	174	17	14351
JUL-2021	7438	780	9	12	170	166	3	14371
AUG-2021	7436	786	16	12	174	167	-2	14393
SEP-2021	7400	829	14	9	174	199	-36	14423
OCT-2021	7393	832	17	6	186	174	-7	14446
NOV-2021	7418	816	11	15	199	175	25	14472
DEC-2021	7431	796	22	6	204	174	13	14490
JAN-2022	7433	788	19	7	161	144	2	14505
FEB-2022	7374	858	8	9	151	211	-59	14530
MAR-2022	7435	802	16	9	232	160	61	14559
APR-2022	7403	836	11	1	159	179	-32	14579
MAY-2022	7456	778	13	13	204	146	53	14603

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2021	205	6681	452	46	7384	2.78%	90.48%	6.12%	0.62%	100.00%
FEB-2021	226	6653	448	51	7378	3.06%	90.17%	6.07%	0.69%	100.00%
MAR-2021	249	6670	463	51	7433	3.35%	89.73%	6.23%	0.69%	100.00%
APR-2021	275	6644	454	44	7417	3.71%	89.58%	6.12%	0.59%	100.00%
MAY-2021	299	6640	465	48	7452	4.01%	89.10%	6.24%	0.64%	100.00%
JUN-2021	326	6613	471	46	7456	4.37%	88.69%	6.32%	0.62%	100.00%
JUL-2021	354	6590	470	46	7460	4.75%	88.34%	6.30%	0.62%	100.00%
AUG-2021	381	6571	471	42	7465	5.10%	88.02%	6.31%	0.56%	100.00%
SEP-2021	398	6525	462	47	7432	5.36%	87.80%	6.22%	0.63%	100.00%
OCT-2021	409	6517	460	46	7432	5.50%	87.69%	6.19%	0.62%	100.00%
NOV-2021	438	6508	457	43	7446	5.88%	87.40%	6.14%	0.58%	100.00%
DEC-2021	468	6492	457	45	7462	6.27%	87.00%	6.12%	0.60%	100.00%
JAN-2022	499	6468	455	43	7465	6.68%	86.64%	6.10%	0.58%	100.00%
FEB-2022	525	6371	445	45	7386	7.11%	86.26%	6.02%	0.61%	100.00%
MAR-2022	550	6408	455	45	7458	7.37%	85.92%	6.10%	0.60%	100.00%
APR-2022	567	6359	450	46	7422	7.64%	85.68%	6.06%	0.62%	100.00%
MAY-2022	597	6383	452	47	7479	7.98%	85.35%	6.04%	0.63%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	2 10%	3153 44%	1 5%	2880 40%	0 0%	28 0%	12 60%	2220 31%	6 30%	1963 27%	18 90%	4046 56%
FEB-2021	2 8%	3135 43%	2 8%	2843 39%	0 0%	27 0%	16 67%	2298 32%	6 25%	1900 26%	22 92%	4062 56%
MAR-2021	8 22%	3140 43%	7 19%	2832 39%	0 0%	24 0%	23 62%	2368 33%	6 16%	1859 26%	29 78%	4112 57%
APR-2021	2 8%	3137 43%	2 8%	2802 39%	0 0%	25 0%	17 68%	2422 33%	6 24%	1791 25%	23 92%	4104 57%
MAY-2021	7 24%	3150 43%	3 10%	2784 38%	0 0%	22 0%	15 52%	2497 34%	10 34%	1759 24%	22 76%	4131 57%
JUN-2021	4 15%	3137 43%	3 12%	2741 38%	0 0%	23 0%	17 65%	2574 35%	5 19%	1698 23%	22 85%	4153 57%
JUL-2021	3 15%	3126 43%	2 10%	2707 37%	0 0%	23 0%	13 65%	2626 36%	4 20%	1655 23%	17 85%	4166 57%
AUG-2021	1 5%	3109 43%	1 5%	2667 37%	0 0%	23 0%	16 73%	2660 36%	5 23%	1631 22%	21 95%	4182 57%
SEP-2021	4 13%	3078 42%	2 7%	2614 36%	1 3%	22 0%	21 70%	2707 37%	5 17%	1587 22%	26 87%	4178 57%
OCT-2021	5 22%	3082 42%	5 22%	2591 36%	0 0%	20 0%	13 57%	2755 38%	5 22%	1563 21%	18 78%	4196 58%
NOV-2021	3 12%	3071 42%	2 8%	2552 35%	0 0%	19 0%	18 72%	2812 39%	4 16%	1534 21%	22 88%	4216 58%
DEC-2021	3 18%	3067 42%	1 6%	2514 34%	0 0%	19 0%	10 59%	2861 39%	5 29%	1503 21%	14 82%	4237 58%
JAN-2022	3 20%	3064 42%	3 20%	2480 34%	0 0%	19 0%	12 80%	2922 40%	0 0%	1473 20%	12 80%	4262 58%
FEB-2022	6 24%	3019 42%	3 12%	2410 33%	2 8%	19 0%	15 60%	2939 41%	4 16%	1395 19%	19 76%	4225 58%
MAR-2022	3 10%	3034 41%	2 7%	2406 33%	0 0%	19 0%	24 83%	3029 41%	2 7%	1350 18%	26 90%	4272 58%
APR-2022	4 20%	3022 42%	3 15%	2369 33%	0 0%	19 0%	14 70%	3052 42%	2 10%	1313 18%	16 80%	4250 58%
MAY-2022	4 17%	3028 41%	3 13%	2356 32%	0 0%	18 0%	17 74%	3144 43%	2 9%	1283 17%	19 83%	4309 59%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		saquinavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	0 0%	1 0%	0 0%	656 32%	5 100%	1297 64%	0 0%	71 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2021	0 0%	1 0%	0 0%	644 33%	5 100%	1262 64%	0 0%	71 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
MAR-2021	0 0%	1 0%	1 25%	622 32%	3 75%	1261 64%	0 0%	73 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
APR-2021	0 0%	1 0%	0 0%	595 31%	4 100%	1230 65%	0 0%	72 4%	0 0%	1 0%	0 0%	2 0%	0 0%	1 0%
MAY-2021	0 0%	1 0%	0 0%	589 31%	4 100%	1239 65%	0 0%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUN-2021	0 0%	1 0%	0 0%	573 31%	4 80%	1221 66%	1 20%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUL-2021	0 0%	1 0%	0 0%	560 30%	6 100%	1216 66%	0 0%	68 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
AUG-2021	0 0%	0 0%	0 0%	547 30%	2 100%	1205 66%	0 0%	66 4%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
SEP-2021	0 0%	1 0%	0 0%	536 30%	2 100%	1184 66%	0 0%	61 3%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
OCT-2021	0 0%	1 0%	0 0%	515 29%	3 100%	1183 67%	0 0%	59 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
NOV-2021	0 0%	1 0%	0 0%	508 29%	3 75%	1171 68%	1 25%	58 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
DEC-2021	0 0%	1 0%	0 0%	492 29%	2 100%	1152 68%	0 0%	58 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
JAN-2022	0 0%	1 0%	0 0%	476 29%	0 0%	1132 68%	0 0%	60 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
FEB-2022	0 0%	1 0%	1 33%	447 28%	1 33%	1110 69%	1 33%	60 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
MAR-2022	0 0%	1 0%	0 0%	430 27%	2 100%	1113 70%	0 0%	57 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
APR-2022	0 0%	1 0%	0 0%	424 27%	0 0%	1085 69%	0 0%	56 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
MAY-2022	0 0%	1 0%	1 33%	417 27%	2 67%	1081 70%	0 0%	53 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	0 0%	11 1%	1 100%	426 34%	0 0%	164 13%	0 0%	379 30%	0 0%	272 22%
FEB-2021	0 0%	15 1%	0 0%	418 34%	0 0%	161 13%	0 0%	365 30%	0 0%	267 22%
MAR-2021	0 0%	21 2%	2 100%	419 34%	0 0%	162 13%	0 0%	365 30%	0 0%	266 22%
APR-2021	0 0%	20 2%	1 50%	409 34%	0 0%	155 13%	1 50%	359 30%	0 0%	260 22%
MAY-2021	1 20%	30 3%	3 60%	397 33%	0 0%	154 13%	0 0%	353 30%	1 20%	259 22%
JUN-2021	0 0%	41 4%	2 100%	379 32%	0 0%	155 13%	0 0%	345 30%	0 0%	251 22%
JUL-2021	0 0%	45 4%	1 100%	371 32%	0 0%	153 13%	0 0%	339 29%	0 0%	243 21%
AUG-2021	0 0%	56 5%	1 100%	366 32%	0 0%	150 13%	0 0%	337 29%	0 0%	241 21%
SEP-2021	0 0%	67 6%	3 75%	357 31%	0 0%	146 13%	0 0%	332 29%	1 25%	242 21%
OCT-2021	1 14%	81 7%	1 14%	350 31%	1 14%	142 12%	1 14%	326 29%	3 43%	244 21%
NOV-2021	0 0%	92 8%	1 33%	346 30%	0 0%	142 13%	0 0%	318 28%	2 67%	244 21%
DEC-2021	0 0%	98 9%	3 75%	340 30%	0 0%	134 12%	0 0%	316 28%	1 25%	243 22%
JAN-2022	0 0%	103 9%	0 0%	328 30%	0 0%	130 12%	0 0%	317 29%	0 0%	235 21%
FEB-2022	0 0%	106 10%	0 0%	317 29%	0 0%	127 12%	0 0%	306 28%	1 100%	228 21%
MAR-2022	0 0%	113 11%	1 100%	303 28%	0 0%	132 12%	0 0%	301 28%	0 0%	222 21%
APR-2022	1 50%	124 12%	1 50%	302 28%	0 0%	130 12%	0 0%	297 28%	0 0%	223 21%
MAY-2022	0 0%	136 13%	0 0%	288 27%	0 0%	128 12%	0 0%	290 27%	1 100%	220 21%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	12 80%	1697 34%	3 20%	2461 49%	0 0%	442 9%	0 0%	27 1%	0 0%	469 9%
FEB-2021	14 64%	1774 35%	5 23%	2476 49%	3 14%	420 8%	0 0%	24 0%	0 0%	457 9%
MAR-2021	23 72%	1839 35%	9 28%	2491 48%	0 0%	418 8%	0 0%	24 0%	0 0%	454 9%
APR-2021	15 75%	1901 36%	4 20%	2504 48%	1 5%	412 8%	0 0%	22 0%	0 0%	438 8%
MAY-2021	15 65%	1979 37%	7 30%	2509 47%	0 0%	397 7%	0 0%	22 0%	1 4%	439 8%
JUN-2021	16 76%	2056 38%	4 19%	2498 47%	1 5%	387 7%	0 0%	23 0%	0 0%	440 8%
JUL-2021	13 81%	2111 39%	3 19%	2498 46%	0 0%	382 7%	0 0%	23 0%	0 0%	432 8%
AUG-2021	15 71%	2150 40%	5 24%	2488 46%	1 5%	374 7%	0 0%	23 0%	0 0%	424 8%
SEP-2021	18 72%	2192 40%	5 20%	2470 46%	2 8%	366 7%	0 0%	23 0%	0 0%	411 8%
OCT-2021	11 73%	2234 41%	3 20%	2469 45%	1 7%	363 7%	0 0%	24 0%	0 0%	398 7%
NOV-2021	17 77%	2303 42%	4 18%	2459 45%	1 5%	348 6%	0 0%	24 0%	0 0%	392 7%
DEC-2021	8 57%	2348 42%	5 36%	2463 45%	1 7%	349 6%	0 0%	24 0%	0 0%	380 7%
JAN-2022	11 73%	2421 43%	2 13%	2468 44%	1 7%	347 6%	0 0%	24 0%	1 7%	374 7%
FEB-2022	15 71%	2443 44%	6 29%	2437 44%	0 0%	331 6%	0 0%	21 0%	0 0%	369 7%
MAR-2022	23 85%	2536 45%	3 11%	2460 43%	1 4%	324 6%	0 0%	21 0%	0 0%	370 7%
APR-2022	14 74%	2574 45%	5 26%	2438 43%	0 0%	312 5%	0 0%	20 0%	0 0%	366 6%
MAY-2022	17 77%	2665 46%	5 23%	2456 43%	0 0%	309 5%	0 0%	22 0%	0 0%	360 6%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2021	1273	17.24	912	12.35	4191	56.76	202	2.74	693	9.39	113	1.53
FEB-2021	1233	16.71	894	12.12	4226	57.28	223	3.02	689	9.34	113	1.53
MAR-2021	1210	16.28	890	11.97	4274	57.50	246	3.31	707	9.51	106	1.43
APR-2021	1166	15.72	868	11.70	4319	58.23	273	3.68	690	9.30	101	1.36
MAY-2021	1146	15.38	858	11.51	4348	58.35	296	3.97	704	9.45	100	1.34
JUN-2021	1125	15.09	834	11.19	4370	58.61	324	4.35	705	9.46	98	1.31
JUL-2021	1104	14.80	820	10.99	4383	58.75	352	4.72	702	9.41	99	1.33
AUG-2021	1090	14.60	817	10.94	4384	58.73	377	5.05	700	9.38	97	1.30
SEP-2021	1070	14.40	812	10.93	4370	58.80	394	5.30	694	9.34	92	1.24
OCT-2021	1053	14.17	809	10.89	4387	59.03	406	5.46	685	9.22	92	1.24
NOV-2021	1038	13.94	804	10.80	4396	59.04	435	5.84	682	9.16	91	1.22
DEC-2021	1020	13.67	790	10.59	4416	59.18	464	6.22	682	9.14	90	1.21
JAN-2022	985	13.19	773	10.35	4452	59.64	496	6.64	673	9.02	86	1.15
FEB-2022	958	12.97	750	10.15	4409	59.69	522	7.07	667	9.03	80	1.08
MAR-2022	934	12.52	737	9.88	4482	60.10	548	7.35	673	9.02	84	1.13
APR-2022	908	12.23	726	9.78	4474	60.28	565	7.61	669	9.01	80	1.08
MAY-2022	899	12.02	710	9.49	4527	60.53	595	7.96	668	8.93	80	1.07

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2021	9	1	3	0	1	2	170
FEB-2021	13	0	2	3	4	4	360
MAR-2021	24	4	5	3	5	5	280
APR-2021	9	2	1	1	1	4	370
MAY-2021	14	1	1	3	2	4	480
JUN-2021	15	4	1	3	2	4	289
JUL-2021	12	1	2	0	2	4	480
AUG-2021	12	1	1	4	2	2	300
SEP-2021	9	0	1	2	2	3	400
OCT-2021	6	1	0	1	0	2	490
NOV-2021	15	3	3	2	2	3	210
DEC-2021	6	1	1	1	3	0	350
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820
MAY-2022	13	4	1	1	1	6	490

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2021	12393	3843
FEB-2021	12386	3838
MAR-2021	12385	3828
APR-2021	12374	3815
MAY-2021	12369	3803
JUN-2021	12370	3797
JUL-2021	12391	3816
AUG-2021	12385	3822
SEP-2021	12354	3790
OCT-2021	12341	3782
NOV-2021	12344	3773
DEC-2021	12324	3767
JAN-2022	12310	3766
FEB-2022	12334	3781
MAR-2022	12363	3797
APR-2022	12393	3822
MAY-2022	12384	3811

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved


Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7479
May-2022

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
May-2022

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
May-2022

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
May-2022

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
May-2022

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
May-2022

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	5	5	*
	35-49	13	13	*
	50+	26	42	*
	Total HSDA:	44	60	27
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	74	101	56	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	413	561	310	
THOMPSON/CARIBOO/ SHUSWAP	20-34	22	22	14
	35-49	64	69	44
	50+	121	194	92
	Total HSDA:	207	285	150
Total HA:		738	1007	543

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		738	1007	543

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	153	208	114
Male	585	799	429

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	543	56	640	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	22	12
	5 years or more	12	6
	<5 years	10	9
	Total HSDA:	44	27
KOOTENAY BOUNDARY	10 years or more	47	33
	5 years or more	14	11
	<5 years	13	12
	Total HSDA:	74	56
OKANAGAN	10 years or more	273	199
	5 years or more	83	64
	<5 years	57	47
	Total HSDA:	413	310
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	131	100
	5 years or more	47	30
	<5 years	29	20
	Total HSDA:	207	150
Total HA:		738	543

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	473	344
5 years or more	156	111
<5 years	109	88
Total HA:	738	543

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	51	70	12	23
KOOTENAY BOUNDARY	77	135	25	53
OKANAGAN	235	1000	57	307
THOMPSON/CARIBOO/SHUSWAP	146	543	34	129
Total:	509	1748	128	512

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	112

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	33	35	25
	35-49	98	103	66
	50+	252	348	194
	Total HSDA:	389	492	291
FRASER NORTH	20-34	118	118	77
	35-49	356	383	271
	50+	633	998	481
	Total HSDA:	1107	1499	829
FRASER SOUTH	0-19	5	5	5
	20-34	103	105	73
	35-49	294	325	230
	50+	607	912	491
	Total HSDA:	1009	1347	799
Total HA:		2505	3338	1919

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	11	11	11
	20-34	254	258	175
	35-49	748	811	567
	50+	1492	2258	1166
Total HA:		2505	3338	1919

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	607	777	450
Male	1898	2561	1469

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1919	53	650	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	249	189
	5 years or more	76	51
	<5 years	64	51
	Total HSDA:	389	291
FRASER NORTH	10 years or more	680	485
	5 years or more	244	195
	<5 years	183	149
	Total HSDA:	1107	829
FRASER SOUTH	10 years or more	625	492
	5 years or more	228	171
	<5 years	156	136
	Total HSDA:	1009	799
Total HA:		2505	1919

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1554	1166
	5 years or more	548	417
	<5 years	403	336
Total HA:		2505	1919

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	142	519	28	55
FRASER NORTH	258	1596	45	222
FRASER SOUTH	227	1744	50	479
Total:	627	3859	123	756

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	189
FRASER NORTH	683
FRASER SOUTH	456
Total:	1328

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		359	519
RICHMOND	20-34	32	33	17
	35-49	49	51	39
	50+	113	165	96
	Total HSDA:	194	249	152
VANCOUVER	0-19	11	11	9
	20-34	439	454	295
	35-49	1250	1404	892
	50+	2948	5189	2129
	Total HSDA:	4648	7058	3325
Total HA:		5201	7826	3772

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	10
	20-34	501	517	335
	35-49	1382	1546	993
	50+	3306	5751	2434
Total HA:		5201	7826	3772

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	603	956	442
Male	4596	6868	3330
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3772	55	650	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	229	188
	5 years or more	73	61
	<5 years	57	46
	Total HSDA:	359	295
RICHMOND	10 years or more	117	90
	5 years or more	32	23
	<5 years	45	39
	Total HSDA:	194	152
VANCOUVER	10 years or more	3163	2185
	5 years or more	886	653
	<5 years	599	487
	Total HSDA:	4648	3325
Total HA:		5201	3772

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3509	2463
	5 years or more	991	737
	<5 years	701	572
Total HA:		5201	3772

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	183	412	53	77
RICHMOND	44	302	8	91
VANCOUVER	663	11327	206	5349
Total:	890	12041	267	5517

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	78

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		348	506
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		121	169
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		780	1122
Total HA:		1249	1797	976

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	5
	20-34	114	125	78
	35-49	282	323	222
	50+	847	1343	671
Total HA:		1249	1797	976

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	214	312	164
Male	1035	1485	812

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	976	56	590	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	211	178
	5 years or more	82	62
	<5 years	55	45
	Total HSDA:	348	285
NORTH VANCOUVER ISLAND	10 years or more	83	69
	5 years or more	26	13
	<5 years	12	11
	Total HSDA:	121	93
SOUTH VANCOUVER ISLAND	10 years or more	478	345
	5 years or more	157	131
	<5 years	145	122
	Total HSDA:	780	598
Total HA:		1249	976

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	772	592
	5 years or more	265	206
	<5 years	212	178
Total HA:		1249	976

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	202	912	75	196
NORTH VANCOUVER ISLAND	154	276	38	67
SOUTH VANCOUVER ISLAND	219	1894	38	583
Total:	575	3082	151	846

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	69
NORTH VANCOUVER ISLAND	40
SOUTH VANCOUVER ISLAND	131
Total:	240

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	5	5	0
	35-49	18	21	12
	50+	24	32	12
	Total HSDA:	47	58	24
NORTH WEST	20-34	*	6	0
	35-49	*	38	19
	50+	*	75	38
	Total HSDA:	72	119	57
NORTHERN INTERIOR	0-19	6	6	*
	20-34	21	22	*
	35-49	56	73	*
	50+	110	187	*
	Total HSDA:	193	288	144
Total HA:		312	465	225

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	30	33	*
	35-49	98	132	*
	50+	178	294	*
Total HA:		312	465	225

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	114	173	80
Male	198	292	145

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	225	53	580	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	29	*
	5 years or more	6	*
	<5 years	12	*
	Total HSDA:	47	24
NORTH WEST	10 years or more	50	38
	5 years or more	12	11
	<5 years	10	8
	Total HSDA:	72	57
NORTHERN INTERIOR	10 years or more	97	76
	5 years or more	58	42
	<5 years	38	26
	Total HSDA:	193	144
Total HA:		312	225

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	176	129
	5 years or more	76	54
	<5 years	60	42
Total HA:		312	225

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	38	61	3	*
NORTH WEST	85	169	20	*
NORTHERN INTERIOR	120	494	20	*
Total:	243	724	43	234

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	*
NORTH WEST	*
NORTHERN INTERIOR	*
Total:	36

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	5	11	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	29	48	*
	THOMPSON/CARIBOO/SHUSWAP	26	50	*
	Total HA:	66	118	47
FRASER	FRASER EAST	36	49	28
	FRASER NORTH	53	93	42
	FRASER SOUTH	83	118	58
	Total HA:	172	260	128
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	32	55	29
	RICHMOND	6	11	5
	VANCOUVER	464	897	366
	Total HA:	502	963	400
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	45	79	37
	NORTH VANCOUVER ISLAND	13	25	9
	SOUTH VANCOUVER ISLAND	46	93	38
	Total HA:	104	197	84
NORTHERN	NORTH EAST	10	14	6
	NORTH WEST	31	66	25
	NORTHERN INTERIOR	67	113	55
	Total HA:	108	193	86
Total:		952	1731	745

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	604	1111	474
Female	348	620	271

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	745	53	500	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.





Monthly Report

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.





Monthly Report

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.





Monthly Report

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

